ethyl 3-[(2S)-2-methylpiperazin-1-yl]propanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: ethyl 3-[(2S)-2-methylpiperazin-1-yl]propanoate
• 化学式: C₁₀H₂₀N₂O₂
• 分子量: 200.28
• InChiKey: ALYHWIYUQAFECE-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] CCR2 MODULATORS<br/>[FR] MODULATEURS DU CCR2
  申请人：CHEMOCENTRYX INC

  公开号：WO2016187393A1

  公开（公告）日：2016-11-24

  Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I) and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of CCR2 receptors.

  提供了一些调节CCR2受体的化合物。这些化合物具有一般公式(I)，在制药组合物、治疗涉及CCR2受体病理性激活的疾病和疾病的方法中是有用的。
• 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP3153511A1

  公开（公告）日：2017-04-12

  To provide a compound useful as an active ingredient of a pharmacological composition for the treatment of urinary storage symptoms, dysuria, lower urinary tract diseases, and the like. [Solution] The inventors perfected the present invention after discovering that thiazole derivatives substituted at position 2 by pyrazinylcarbonylamino are exceptional muscarinic M3 receptor positive allosteric modulators and can be expected to serve as agents for the prevention or treatment of urinary bladder and urinary tract diseases involving bladder contraction mediated by muscarinic M3 receptors. The 2-acylaminothiazole derivatives or salts thereof of the present invention can be expected to serve as agents for the prevention or treatment of urinary bladder and urinary tract diseases involving bladder contraction mediated by muscarinic M3 receptors, e.g., underactive bladder and the like.

  提供一种化合物，作为治疗储尿症状、排尿困难、下尿路疾病等的药理组合物的有效成分。[解决方案]本发明者发现在第 2 位被吡嗪基羰基氨基取代的噻唑衍生物是一种特殊的毒蕈碱 M3 受体正异位调节剂，可望作为预防或治疗涉及毒蕈碱 M3 受体介导的膀胱收缩的膀胱和尿路疾病的药物，从而完善了本发明。本发明的2-乙酰氨基噻唑衍生物或其盐可望用作预防或治疗涉及毒蕈碱M3受体介导的膀胱收缩的膀胱和尿路疾病的药物，例如膀胱功能不全等。
• 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP3196200A1

  公开（公告）日：2017-07-26

  [Problem] To provide a compound useful as an active ingredient in a pharmaceutical composition for treating bladder storage disorders, dysuria, lower urinary tract diseases, and the like. [Solution] The inventors of the present invention have discovered that a 2-aminothiazole derivative exhibits an excellent muscarinic M3 receptor positive allosteric modulator activity, and has potential as a preventative or therapeutic agent against bladder and urinary tract diseases to which bladder contraction mediated by muscarinic M3 receptors contributes. The 2-aminothiazole derivative or salt thereof has potential as a preventative or therapeutic agent against bladder and urinary tract diseases such as, for example, dysuria including underactive bladder, and to which bladder contraction mediated by muscarinic M3 receptors contributes.

  [问题]提供一种化合物，作为药物组合物中的活性成分，用于治疗膀胱储尿障碍、排尿困难、下尿路疾病等。[解决方案]本发明的发明者发现，一种 2-氨基噻唑衍生物表现出优异的毒蕈碱 M3 受体正异位调节剂活性，具有作为膀胱和尿路疾病预防或治疗剂的潜力，膀胱和尿路疾病是由毒蕈碱 M3 受体介导的膀胱收缩造成的。2- 氨基噻唑衍生物或其盐具有预防或治疗膀胱和尿路疾病的潜力，例如，排尿困难，包括膀胱活动不足，而毒蕈碱 M3 受体介导的膀胱收缩是导致这些疾病的原因。
• Substituted tetrahydropyrans as CCR2 modulators
  申请人：CHEMOCENTRYX, INC.

  公开号：US10464934B2

  公开（公告）日：2019-11-05

  Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.

  所提供的化合物是 CCR2 受体的调节剂。这些化合物具有通式 (I)： 并可用于药物组合物、治疗涉及 CCR2 受体病理性激活的疾病和失调的方法。
• 2-AMINOTHIAZOLE DERIVATIVES OR SALT THEREOF AS MUSCARINIC M3 LIGANDS FOR THE TREATMENT OF BLADDER DISEASES
  申请人：Astellas Pharma Inc.

  公开号：EP3196200B1

  公开（公告）日：2019-05-08